BioPharmSignal logoBioPharmSignal

Biotech News

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Corcept (CORT)CorceptEarnings

2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 REDWOOD CITY, Calif. --(BUSINESS WIRE)--Feb. 24, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a

Related news

CORTCorcept2026-07-29 20:05 EST

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-07-22 20:05 EST

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-04-29 20:05 EST

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

CRNXCrinetics Pharmaceuticals2026-02-26 21:05 EST

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

CRNXCrinetics Pharmaceuticals2026-01-26 22:00 EST

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-07-09 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

AMPHAmphastar Pharmaceuticals, Inc.2021-03-15 20:05 EST

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020

AMPHAmphastar Pharmaceuticals, Inc.2021-03-08 22:39 EST

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021

View all latest news

Corcept

Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...

Recent company news

CORTCorcept2026-07-29 20:05 EST

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-07-22 20:05 EST

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORTCorcept2026-06-17 20:28 EST

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-06-06 20:45 EST

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

CORTCorcept2026-05-29 20:33 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Stock data

Close
122.25 USD
Market cap
7.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States